These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 34107497)

  • 1. Sonic Hedgehog Pathway Blockade After Surgical Debulk of Large Exophytic Basal Cell Carcinomas.
    Wirth PJ; Hobbs R; Billingsley E; Vidimos AT; Lam C
    Dermatol Surg; 2021 Aug; 47(8):1118-1119. PubMed ID: 34107497
    [No Abstract]   [Full Text] [Related]  

  • 2. Cells to surgery quiz: October 2014.
    Falto-Aizpurua L; Griffith RD; Abyaneh MY; Nouri K
    J Invest Dermatol; 2014 Oct; 134(10):1-2. PubMed ID: 25219654
    [No Abstract]   [Full Text] [Related]  

  • 3. Palliative Use of Vismodegib.
    Lam C; Larson E; Vidimos AT; Billingsley EM
    Dermatol Surg; 2020 Feb; 46(2):272-276. PubMed ID: 30789523
    [No Abstract]   [Full Text] [Related]  

  • 4. Noninvasive monitoring of basal cell carcinomas treated with systemic hedgehog inhibitors: pseudocysts as a sign of tumor regression.
    Maier T; Kulichova D; Ruzicka T; Berking C
    J Am Acad Dermatol; 2014 Oct; 71(4):725-30. PubMed ID: 24928708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sonic Hedgehog pathway inhibitors: from clinical trials to clinical practice.
    Yan BY; Hibler BP; Menge T; Dunn L; Ho AL; Rossi AM
    Br J Dermatol; 2019 May; 180(5):1260-1261. PubMed ID: 30693471
    [No Abstract]   [Full Text] [Related]  

  • 6. Vismodegib Efficacy in Advanced Basal Cell Carcinoma Maintained with 8-Week Dose Interruptions: A Model-Based Evaluation.
    Chanu P; Musib L; Wang X; Cheeti S; Girish S; Bruno R; Lu T; Reddy J; Jin JY; Caro I
    J Invest Dermatol; 2021 Apr; 141(4):930-933. PubMed ID: 32976880
    [No Abstract]   [Full Text] [Related]  

  • 7. PRISModegib: the use of the PRISM test to assess the health-related quality of life of patients with locally advanced basal cell carcinoma undergoing Hedgehog pathway inhibitor therapy.
    Gualdi G; Moro R; Regina V; Caravello S; Monari P; Calzavara-Pinton PG
    Br J Dermatol; 2019 Aug; 181(2):406-407. PubMed ID: 30737996
    [No Abstract]   [Full Text] [Related]  

  • 8. A randomized phase II study evaluating vismodegib as neoadjuvant treatment of basal cell carcinoma preceding Mohs micrographic surgery: results and lessons learned.
    Soon SL; Ibrahim SF; Arron ST
    Br J Dermatol; 2019 Jul; 181(1):208-209. PubMed ID: 30628055
    [No Abstract]   [Full Text] [Related]  

  • 9. Metastatic spinal cord compression from basal cell carcinoma of the skin treated with surgical decompression and vismodegib: case report and review of Hedgehog signalling pathway inhibition in advanced basal cell carcinoma.
    McGrane J; Carswell S; Talbot T
    Clin Exp Dermatol; 2017 Jan; 42(1):80-83. PubMed ID: 27905158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Vismodegib Experience in Elderly Patients with Basal Cell Carcinoma: Case Reports and Review of the Literature.
    Passarelli A; Galdo G; Aieta M; Fabrizio T; Villonio A; Conca R
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33202689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vismodegib as a neoadjuvant treatment to Mohs surgery for aggressive basal cell carcinoma.
    Alcalay J; Tauber G; Fenig E; Hodak E
    J Drugs Dermatol; 2015 Mar; 14(3):219-23. PubMed ID: 25738842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Managing adverse effects by dose reduction during routine treatment of locally advanced basal cell carcinoma with the hedgehog inhibitor vismodegib: a single centre experience.
    Woltsche N; Pichler N; Wolf I; Di Meo N; Zalaudek I
    J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):e144-e145. PubMed ID: 30472793
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety and efficacy of vismodegib in patients aged ≥65 years with advanced basal cell carcinoma.
    Chang AL; Lewis KD; Arron ST; Migden MR; Solomon JA; Yoo S; Day BM; McKenna EF; Sekulic A
    Oncotarget; 2016 Nov; 7(46):76118-76124. PubMed ID: 27764798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hedgehog- and mTOR-targeted therapies for advanced basal cell carcinomas.
    Piérard-Franchimont C; Hermanns-Lê T; Paquet P; Herfs M; Delvenne P; Piérard GE
    Future Oncol; 2015 Nov; 11(22):2997-3002. PubMed ID: 26437034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Novel Alternate Dosing of Vismodegib for Treatment of Patients With Advanced Basal Cell Carcinomas.
    Becker LR; Aakhus AE; Reich HC; Lee PK
    JAMA Dermatol; 2017 Apr; 153(4):321-322. PubMed ID: 28114606
    [No Abstract]   [Full Text] [Related]  

  • 16. A cell identity switch allows residual BCC to survive Hedgehog pathway inhibition.
    Biehs B; Dijkgraaf GJP; Piskol R; Alicke B; Boumahdi S; Peale F; Gould SE; de Sauvage FJ
    Nature; 2018 Oct; 562(7727):429-433. PubMed ID: 30297801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes for Basal Cell Carcinoma Treated With Vismodegib Extended Alternate Day Dosing.
    Routt E; Ratner D
    Dermatol Surg; 2020 Aug; 46(8):1109-1112. PubMed ID: 31274526
    [No Abstract]   [Full Text] [Related]  

  • 18. Radiation Sensitization of Basal Cell and Head and Neck Squamous Cell Carcinoma by the Hedgehog Pathway Inhibitor Vismodegib.
    Hehlgans S; Booms P; Güllülü Ö; Sader R; Rödel C; Balermpas P; Rödel F; Ghanaati S
    Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30142876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vismodegib as Eye-Sparing Neoadjuvant Treatment for Locally Advanced Periocular Basal Cell Carcinoma.
    Angnardo L; Humeda Y; Alexandraki I; Wolfe CM; Cognetta AB
    J Drugs Dermatol; 2021 May; 20(5):552-554. PubMed ID: 33938701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current landscape for treatment of advanced basal cell carcinoma.
    Foley P
    Australas J Dermatol; 2015 Mar; 56 Suppl 1():1-7. PubMed ID: 25715811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.